Dimensional Fund Advisors LP Purchases 198,936 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Dimensional Fund Advisors LP boosted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 12.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,828,065 shares of the company's stock after purchasing an additional 198,936 shares during the quarter. Dimensional Fund Advisors LP owned 3.93% of Pacira BioSciences worth $52,300,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PCRX. WINTON GROUP Ltd acquired a new position in shares of Pacira BioSciences in the 2nd quarter valued at $2,726,000. Retirement Planning Co of New England Inc. bought a new position in Pacira BioSciences during the second quarter worth about $297,000. Thornburg Investment Management Inc. acquired a new position in Pacira BioSciences in the second quarter valued at about $5,396,000. American Century Companies Inc. increased its holdings in shares of Pacira BioSciences by 16.6% in the second quarter. American Century Companies Inc. now owns 69,498 shares of the company's stock worth $1,988,000 after acquiring an additional 9,911 shares in the last quarter. Finally, Van Hulzen Asset Management LLC raised its position in shares of Pacira BioSciences by 86.6% during the second quarter. Van Hulzen Asset Management LLC now owns 64,166 shares of the company's stock worth $1,836,000 after purchasing an additional 29,784 shares during the period. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Stock Up 1.5 %

NASDAQ:PCRX traded up $0.21 on Friday, hitting $14.54. 632,728 shares of the company's stock were exchanged, compared to its average volume of 1,142,013. The firm has a 50-day moving average price of $15.84 and a 200-day moving average price of $23.46. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $35.95. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.82 and a quick ratio of 5.70. The company has a market cap of $670.73 million, a P/E ratio of 10.17 and a beta of 0.84.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.53 by $0.11. The firm had revenue of $178.02 million during the quarter, compared to analysts' expectations of $173.31 million. Pacira BioSciences had a return on equity of 13.22% and a net margin of 9.21%. As a group, analysts expect that Pacira BioSciences, Inc. will post 2.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PCRX shares. Needham & Company LLC cut their price objective on Pacira BioSciences from $43.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, August 12th. Truist Financial lowered shares of Pacira BioSciences from a "buy" rating to a "sell" rating and cut their price target for the company from $30.00 to $8.00 in a research note on Tuesday, August 13th. JPMorgan Chase & Co. reissued an "underweight" rating and set a $10.00 price objective (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Barclays cut shares of Pacira BioSciences from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $38.00 to $25.00 in a research report on Wednesday, July 3rd. Finally, HC Wainwright reduced their target price on shares of Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating for the company in a research note on Monday, August 12th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $24.10.

Insider Activity

In other news, CEO Frank D. Lee purchased 8,264 shares of the business's stock in a transaction on Monday, August 12th. The stock was purchased at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the purchase, the chief executive officer now directly owns 107,784 shares in the company, valued at approximately $1,304,186.40. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Pacira BioSciences news, CEO Frank D. Lee bought 8,264 shares of Pacira BioSciences stock in a transaction dated Monday, August 12th. The stock was bought at an average cost of $12.10 per share, for a total transaction of $99,994.40. Following the purchase, the chief executive officer now owns 107,784 shares of the company's stock, valued at approximately $1,304,186.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jonathan Slonin sold 2,836 shares of the business's stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the transaction, the insider now directly owns 95,557 shares in the company, valued at $2,699,485.25. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 11,176 shares of company stock valued at $136,240 and sold 4,281 shares valued at $105,494. 6.40% of the stock is currently owned by insiders.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.